Interpace Biosciences Inc (IDXG)
1.50
-0.12
(-7.41%)
USD |
OTCM |
Mar 18, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 6.483M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 87.50% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 0.172 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -0.2059 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 98.34% |
Profile
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services. |
URL | https://www.interpace.com |
Investor Relations URL | http://phx.corporate-ir.net/phoenix.zhtml?c=73639&p=irol-irhome |
HQ State/Province | New Jersey |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Small Cap/Value |
Next Earnings Release | N/A |
Last Earnings Release | Nov. 13, 2019 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services. |
URL | https://www.interpace.com |
Investor Relations URL | http://phx.corporate-ir.net/phoenix.zhtml?c=73639&p=irol-irhome |
HQ State/Province | New Jersey |
Sector | Healthcare |
Industry | Diagnostics & Research |
Equity Style | Small Cap/Value |
Next Earnings Release | N/A |
Last Earnings Release | Nov. 13, 2019 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |